Literature DB >> 2884368

Clonidine treatment for short stature.

C Pintor, S G Cella, S Loche, R Puggioni, R Corda, V Locatelli, E E Müller.   

Abstract

34 pubertal children with constitutional growth delay (CGD) were treated with clonidine orally twice a day. In 25 of the children the height velocity rose on clonidine treatment, and in 21 of them by more than 2 cm/yr during the first 6 months of treatment (mean [SD] growth increment 4.4 [0.5] cm/yr). Of the 22 who were treated for 12 months the increment in height velocity was maintained in 13 (3.4[0.4] cm/yr). Withdrawal of clonidine for 6 months did not stop the stimulatory effect of the drug on linear growth in 6 children, but in the other 8 children height velocities fell to pretreatment levels or below. In a few children reinstitution of clonidine for 2-4 months resulted in a new increment in height velocity. A high height standard deviation score and low growth velocity before treatment were predictive of a good growth response to clonidine. Clonidine did not induce noticeable side-effects. It may be a useful form of therapy for children with CGD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884368     DOI: 10.1016/s0140-6736(87)92684-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Effect of a long-term methionyl growth hormone treatment on growth hormone releasing hormone-induced growth hormone secretion in patients with constitutional growth delay.

Authors:  A Sartorio; A Conti; F Morabito; G Faglia
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

Review 2.  Clonidine treatment in children with short stature.

Authors:  S Loche; A Lampis; S G Cella; V Locatelli; E E Müller; C Pintor
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

3.  Effect of clonidine on serum gonadotrophin concentrations.

Authors:  F Darendeliler; D Suri; P Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 4.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

Review 5.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine.

Authors:  F Orio; N Padovano; L Cinquanta; A Colao; B Merola; S Longobardi; E Rossi; V Esposito; F Orio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

7.  Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children.

Authors:  E Ghigo; S Goffi; E Mazza; E Imperiale; E Arvat; J Bellone; M Procopio; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

8.  Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency.

Authors:  Toshiaki Tanaka; Yukihiro Hasegawa; Susumu Yokoya; Yoshikazu Nishi
Journal:  Clin Pediatr Endocrinol       Date:  2014-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.